Gemphire Therapeutics to Announce Fourth Quarter and Year End 2017 Financial Results on Thursday, March 15
March 13 2018 - 9:18AM
Gemphire Therapeutics Inc. (NASDAQ:GEMP), a clinical-stage
biopharmaceutical company focused on developing and commercializing
therapies for cardiometabolic disorders, including dyslipidemia,
non-alcoholic fatty liver disease (NAFLD) and nonalcoholic
steatohepatitis (NASH), today announced that it will host a
conference call and live audio webcast on Thursday, March 15, 2018
at 4:30 p.m. Eastern Time to discuss financial results for the
fourth quarter and year ended December 31, 2017 and to provide a
business update.
Thursday, March 15 at 4:30pm Eastern
Time |
Domestic: |
(844) 494-0188 |
International: |
+1 (425) 278-9114 |
Conference ID |
2090268 |
Webcast: |
https://edge.media-server.com/m6/p/bxoocvxs |
A webcast replay will be available on the News & Events
section of the Gemphire website for all interested parties
following the call and will be archived and available for 90
days.
About GemphireGemphire is a clinical-stage
biopharmaceutical company that is committed to helping patients
with cardiometabolic disorders, including dyslipidemia and
NASH. The Company is focused on providing new treatment
options for cardiometabolic diseases through its complementary,
convenient, cost-effective product candidate gemcabene as add-on to
the standard of care, especially statins, that will benefit
patients, physicians, and payors. Gemphire’s Phase 2 clinical
program is evaluating the efficacy and safety of gemcabene in
hypercholesterolemia, including FH and ASCVD, SHTG and
NASH/NAFLD. Two trials supporting hypercholesterolemia have
been completed under NCT02722408 and NCT02634151. Gemphire
has completed recruitment for a clinical trial for SHTG under
NCT02944383, and has initiated separate trials for adult NASH and
pediatric NAFLD. Please visit www.gemphire.com for more
information.
Contact:Andrew McDonald, Ph.D.LifeSci Advisors,
LLC(646) 597-6987
Jeff Mathiesen, CFOGemphire Therapeutics Inc.(734)-245-1700
Gemphire Therapeutics (NASDAQ:GEMP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Gemphire Therapeutics (NASDAQ:GEMP)
Historical Stock Chart
From Apr 2023 to Apr 2024